CAMBRIDGE, Mass., June 1, 2026
Fulcrum Therapeutics announced the discontinuation of its lead investigational therapy pociredir for the treatment of sickle cell disease (SCD) after receiving feedback from the U.S. Food and Drug Administration (FDA) that effectively eliminated a viable regulatory pathway for the program. The decision follows FDA concerns regarding potential malignancy risks associated with inhibition of the PRC2 complex, a mechanism shared with the recently withdrawn cancer therapy Tazverik® (tazemetostat). Alongside the program termination, Fulcrum has launched a comprehensive strategic review to evaluate alternatives aimed at maximizing shareholder value, including potential mergers, acquisitions, business combinations, or other strategic transactions.
FDA Feedback Raises Significant Regulatory Concerns
The company received official FDA meeting minutes on May 28, 2026, following end-of-phase discussions regarding the future development of pociredir. FDA concerns were influenced by the unexpectedly high incidence of secondary hematologic malignancies reported with Tazverik, an EZH2 inhibitor that was voluntarily withdrawn from global markets earlier this year. Fulcrum argued that pociredir targets EED, a distinct component of the PRC2 complex, and that biological differences between EED and EZH2 should be considered in evaluating risk. However, the FDA concluded that pharmacological targeting of any component of the PRC2 complex may carry a similar malignancy risk, regardless of the specific subunit involved. Combined with previously disclosed preclinical malignancy findings, the agency determined that the overall benefit-risk profile did not support continued clinical development.
Promising Efficacy Overshadowed by Safety and Regulatory Challenges
Pociredir had generated considerable interest within the sickle cell disease community due to its ability to significantly increase fetal hemoglobin (HbF) levels, a validated therapeutic strategy for reducing disease severity and complications. The small-molecule therapy was designed to address the underlying biology of sickle cell disease by reactivating fetal hemoglobin production. Importantly, Fulcrum reported that no new clinical safety signals had been observed during development. Nevertheless, the regulatory concerns surrounding potential long-term malignancy risk ultimately outweighed the promising efficacy signals. Company leadership described the decision as difficult, particularly given the substantial unmet need for innovative treatments in the sickle cell disease community.
Advertisement
Company Focus Shifts to Strategic Alternatives and Capital Preservation
With the termination of the pociredir program, Fulcrum is now focused on preserving capital and evaluating strategic options for the future of the company. Management has initiated significant cost-reduction measures while reviewing opportunities that may unlock value from its remaining assets and capabilities. As of March 31, 2026, Fulcrum reported approximately $333.3 million in cash, cash equivalents, and marketable securities, providing financial flexibility as the review process proceeds. The company stated that it does not intend to provide additional updates until a strategic direction has been approved by its Board of Directors or the review process has been completed. The announcement marks a major turning point for Fulcrum as it reassesses its future following the loss of its lead clinical program.
Source: Fulcrum Therapeutics,press release
